What happens when a promising therapy falls short? Medscape spoke with Jeffrey Cummings, MD, who led the EVOKE trials of the GLP-1 semaglutide for AD, about what the results mean — and what comes next.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/semaglutide-alzheimers-disease-what-evoke-trials-taught-us-2026a10006ry?src=rss
Author :
Publish date : 2026-03-05 09:24:00
Copyright for syndicated content belongs to the linked Source.
